default author photo

Mary-Anne Trabaud

Hospices Civils de Lyon - Laboratoire de Virologie

103 Grande Rue de la CroixRousse

Lyon, F-69317

France

SCHOLARLY PAPERS

4

DOWNLOADS

540

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Effects of Remdesivir in Hospitalized Patients with COVID-19: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials

Number of pages: 32 Posted: 11 Oct 2022
Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, Hôpital Bichat, APHP, University of Oslo - Oslo University Hospital, University of Paris, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Hôpital Bichat, APHP, University of British Columbia (UBC), University of North Carolina (UNC) at Chapel Hill - National Institute of Health, Government of the People's Republic of China - Department of Pulmonary and Critical Care Medicine, Helsinki University Hospital, Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Université Libre de Bruxelles (ULB), University of Claude Bernard Lyon 1, Hospices Civils de Lyon - Laboratoire de Virologie, University of Toronto, McGill University - Division of Experimental Medicine, University of Toronto - Sunnybrook Health Sciences Centre, University of Oslo - Oslo University Hospital, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine, University of North Carolina (UNC) at Chapel Hill - National Institute of Health, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - Basel Institute for Clinical Epidemiology and Biostatistics, University of Basel - University Hospital Basel, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital and University of Basel - University Hospital Basel
Downloads 191 (399,431)

Abstract:

Loading...

Remdesivir, COVID-19, systematic review, individual patient data meta analysis, randomized controlled trials, GS-5734

2.

Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Number of pages: 34 Posted: 03 Aug 2022
University of Oslo - Section for Clinical Immunology and Infectious Diseases, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, University of Oslo - Institute of Clinical Medicine, University of Lille, affiliation not provided to SSRN, University of Verona, Hospital Universitario Virgen Macarena - Unidad Clínica de Enfermedades Infecciosas, affiliation not provided to SSRN, Université Libre de Bruxelles (ULB), Medical University of Innsbruck, Government of Portugal - Unidade Local de Saúde de São João, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Division of Emergencies and Critical Care, University of Claude Bernard Lyon 1, affiliation not provided to SSRN, University of Pécs, National and Kapodistrian University of Athens, University Hospital Brno, University of Basel - University Hospital Basel, Hacettepe University, Technische Universität München (TUM), Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, Vestre Viken Hospital Trust, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, University of Oslo - Institute of Clinical Medicine, University of Stavanger - Stavanger University Hospital, Hospital Universitario La Paz, Vestre Viken Hospital Trust, University Hospital North Norway, Hospices Civils de Lyon - Service de Médecine Intensive-Réanimation, Akershus University Hospital - Department of Infectious Diseases, Norwegian Institute of Public Health, Sorbonne University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Department of Immunology and Transfusion Medicine, Hospices Civils de Lyon - Laboratoire de Virologie, University of Nantes - INSERM, University of Oslo - Oslo University Hospital, Norwegian Institute of Public Health, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, affiliation not provided to SSRN, University of Oslo - Department of Research Support for Clinical Trials and Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP
Downloads 176 (428,796)

Abstract:

Loading...

COVID-19, immunomodulator, safety, baricitinib, JAK inhibitor

3.

Clinical and Microbiological Assessments of COVID-19 in Healthcare Workers: A Prospective Longitudinal Study

Number of pages: 28 Posted: 02 Dec 2020
Hospices Civils de Lyon - Laboratoire de Virologie, Lyon Sud Hospital - Joint Research Unit Civils Hospices of Lyon-bioMérieux, Croix Rousse Hospital, CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Université de Toulouse - CHU Toulouse-Purpan, Laboratoire De Virologie, Institut Des Agents Infectieux, Laboratoire Associé Au Centre National De Référence Des Virus Des Infections Respiratoires, Hospices Civils De Lyon, University of Claude Bernard Lyon 1, Hospices Civils de Lyon - Laboratoire de Virologie, Biomérieux, Lyon Sud Hospital, Lyon Sud Hospital, Lyon University, Université Claude Bernard Lyon, Hospices Civils de Lyon - Occupational Health and Medicine Department, Institut de Biologie Structurale, Université Grenoble Alpes, CEA, CNRS and Centre Hospitalier Universitaire Grenoble Alpes, University Grenoble Alpes - Centre Hospitalier Universitaire de Grenoble (CHU Grenoble Alpes), 8GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Université Jean Monnet, Lyon University, The Scripps Research Institute - Department of Immunology and Microbiology, University of Claude Bernard Lyon 1, Hospices Civils de Lyon - Occupational Health and Medicine Department, Croix Rousse Hospital, Hospices Civils de Lyon - Laboratoire de Virologie and Independent
Downloads 143 (514,995)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Health-care workers, viral load, viral culture, RT-PCR, neutralizing antibodies

4.

Evaluation of Commercial Anti-SARS-CoV-2 Neutralizing Antibody Assays in Seropositive Subjects

Number of pages: 17 Posted: 03 Feb 2022
Hospices Civils de Lyon - Laboratoire de Virologie, University of Claude Bernard Lyon 1 - CIRI, Hospices Civils de Lyon - Laboratoire de Virologie, Hospices Civils de Lyon - Occupational Health and Medicine Department, Hospices Civils de Lyon - Occupational Health and Medicine Department, Hospices Civils de Lyon - Laboratoire de Virologie, Université de Lyon - Laboratoire de Biométrie et Biologie Evolutive, Université de Lyon - Laboratoire de Biométrie et Biologie Evolutive, Hospices Civils de Lyon - Occupational Health and Medicine Department, Hospices Civils de Lyon - Occupational Health and Medicine Department, Hospices Civils de Lyon - Occupational Health and Medicine Department, Hospices Civils de Lyon - Laboratoire de Virologie, Hospices Civils de Lyon - Laboratoire de Virologie and Hospices Civils de Lyon - Laboratoire de Virologie
Downloads 30 (1,318,317)

Abstract:

Loading...

SARS-CoV-2, neutralizing antibodies, commercial tests, surrogate markers of protection, competitive anti-RBD immunoassays